Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase  3 Clinical Trials (Measure Up 1 and 2)

ConclusionsOnce-daily oral upadacitinib monotherapy improved response rates across PROs compared with placebo. Upadacitinib therapy resulted in rapid, sustained improvements in PROs measuring symptom burden and QoL in adults and adolescents with moderate-to-severe  AD.Trial RegistrationClinicalTrials.gov identifiers, NCT03569293 and NCT03607422.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research